

Company Overview

SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas.

SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting

Mar 2 2021, 7:30 AM EST

SCYNEXIS to Participate in Maxim Group's Late Stage Innovations in Women's Health Virtual Event

Feb 25 2021, 4:15 PM EST

SCYNEXIS and Amplify Health Announce Agreement to Support the Anticipated U.S. Commercialization of Brexafemme™ (Ibrexafungerp) for Vaginal Yeast Infections

Feb 23 2021, 8:15 AM EST

Stock Overview

Symbol	SCYX
Exchange	Nasdaq
Market Cap	165.42m
Last Price	\$8.58
52-Week	\$4.21 - \$10.50

03/04/2021 04:00 PM EST

Investor Relations

LifeSci Advisors
Irina Koffler
T: 646-970-4681
ikoffler@lifesciadvisors.com

Leadership

Marco Taglietti, M.D.

President and Chief Executive Officer

David Angulo, M.D.

Chief Medical Officer

Eric Francois

Chief Financial Officer

Scott Sukenick

General Counsel

Nkechi Azie, M.D., FIDSA

Vice President, Clinical Development and Medical Affairs

Jim Maffezzoli

Vice President of Marketing and Sales

Rajeshwar Motheram, Ph.D.

Vice President, Pharmaceutical Development

SCYNEXIS, Inc.

1 Evertrust Plaza
13th Floor
Jersey City, NJ 07302

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.